Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Higher sNfL concentrations were associated with worse performance in cognitive tests at baseline, including CERAD (B = −10.084, SE = 2.999, p < 0.001) and MMSE (B = −3.014, SE = 1.293, p = 0.021). The sNfL levels also correlated with the presence of neuropsychiatric symptoms (NPI total score: r = 0.138, p = 0.041) and with smaller volumes of the temporal lobe (B = −0.012, SE = 0.003, p = 0.001), the hippocampus (B = −0.001, SE = 0.000201, p = 0.013), the entorhinal (B = −0.000308, SE = 0.000124, p = 0.014), and the parahippocampal cortex (B = −0.000316, SE = 0.000113, p = 0.006). The sNfL values predicted more pronounced cognitive decline over the mean follow-up period of 22 months, but there were no significant associations with respect to change in neuropsychiatric symptoms and brain volumetric measures. the sNfL levels relate to cognitive, behavioural, and imaging hallmarks of AD and predicts short term cognitive decline.

Key findings

Why it matters

In this study, higher serum NfL levels were linked to worse cognitive test scores and predicted more cognitive decline over about 22 months, but not changes in neuropsychiatric symptoms or brain volumes. This marker may help track short-term cognitive worsening, but the study does not show any treatment, cure, or prevention.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 53 of 100.53 of 100 points earned47 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Medicina (Kaunas, Lithuania))
Journal's citation record 1 / 4 Medicina: journal h-index 107 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 2 / 4 237 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 15 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.5 citations a year over 6 year(s) since 2022
Impact for its field and year 2 / 6 Cited 1.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Reinhold Ernst Schmidt: h-index 100 (OpenAlex, whole career)
Institution's track record 1 / 3 Medical University of Vienna: institution h-index 818 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35334608)
Free to read 2 / 2 Free to read
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Kern, D., Khalil, M., Pirpamer, L., Buchmann, A., Hofer, E., Dal-Bianco, P., et al. (2022). Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria. Medicina (Kaunas, Lithuania). https://doi.org/10.3390/medicina58030433

Vancouver

Kern D, Khalil M, Pirpamer L, Buchmann A, Hofer E, Dal-Bianco P, et al. Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria. Medicina (Kaunas, Lithuania). 2022. doi:10.3390/medicina58030433. PMID: 35334608.

BibTeX

@article{kern2022-35334608,
  author  = {Kern, D. and Khalil, M. and Pirpamer, L. and Buchmann, A. and Hofer, E. and Dal-Bianco, P. and Stögmann, E. and Scherfler, C. and others},
  title   = {{Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria}},
  journal = {Medicina (Kaunas, Lithuania)},
  year    = {2022},
  doi     = {10.3390/medicina58030433},
  pmid    = {35334608},
  url     = {https://doi.org/10.3390/medicina58030433}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Related studies in Biomarkers

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Biomarkers

See all studies in Biomarkers →